To the Editor On the basis of a meta-analysis of 81 publications, Short et al1 reported that measurable residual disease negativity after induction or consolidation was associated with superior disease-free survival and overall survival for patients with acute myeloid leukemia (AML), and both Short et al1 and, in the accompanying Invited Commentary, Jeyakumar and O’Brien2 proposed use of measurable residual disease as an efficacy end point to facilitate drug development.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Przepiorka D, de Claro RA, Pazdur R. The Role of Acute Myeloid Leukemia Minimal Residual Disease in Regulatory Decision-making. JAMA Oncol. 2021;7(5):784. doi:10.1001/jamaoncol.2021.0122
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.